In long-term coculture assays, we found that anti-CD47 antibodies or KRASG12C inhibitors (sotorasib or adagrasib) inhibited cancer cell growth over time but generally had only moderate effects as single agents (Figure 4C). Here, CD47 is linked to cancer.